CN116635413A - 用于获得结合跨膜蛋白的抗体的方法和生产所述抗体的细胞 - Google Patents

用于获得结合跨膜蛋白的抗体的方法和生产所述抗体的细胞 Download PDF

Info

Publication number
CN116635413A
CN116635413A CN202180086859.7A CN202180086859A CN116635413A CN 116635413 A CN116635413 A CN 116635413A CN 202180086859 A CN202180086859 A CN 202180086859A CN 116635413 A CN116635413 A CN 116635413A
Authority
CN
China
Prior art keywords
transmembrane protein
interest
protein
cells
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180086859.7A
Other languages
English (en)
Chinese (zh)
Inventor
G·陈
E·史
W-Y·李
D·苏
G·法尔
R·巴布
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN116635413A publication Critical patent/CN116635413A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN202180086859.7A 2020-12-23 2021-12-22 用于获得结合跨膜蛋白的抗体的方法和生产所述抗体的细胞 Pending CN116635413A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063130044P 2020-12-23 2020-12-23
US63/130,044 2020-12-23
PCT/US2021/064769 WO2022140494A1 (en) 2020-12-23 2021-12-22 Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same

Publications (1)

Publication Number Publication Date
CN116635413A true CN116635413A (zh) 2023-08-22

Family

ID=82022075

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180086859.7A Pending CN116635413A (zh) 2020-12-23 2021-12-22 用于获得结合跨膜蛋白的抗体的方法和生产所述抗体的细胞

Country Status (12)

Country Link
US (2) US12371487B2 (https=)
EP (1) EP4267608A1 (https=)
JP (1) JP2024501796A (https=)
KR (1) KR20230124594A (https=)
CN (1) CN116635413A (https=)
AU (1) AU2021409906A1 (https=)
BR (1) BR112023011689A2 (https=)
CA (1) CA3197426A1 (https=)
IL (1) IL303865A (https=)
MX (1) MX2023007583A (https=)
TW (1) TW202242114A (https=)
WO (1) WO2022140494A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118027202A (zh) * 2024-03-14 2024-05-14 恺佧生物科技(上海)有限公司 结合slc13a5膜蛋白的抗体

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116622754A (zh) * 2023-05-31 2023-08-22 南开大学 一种定点标记的跨膜蛋白纳米盘及其制备方法和应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DK1345959T3 (da) 2000-11-20 2011-09-05 Univ Illinois Membranscaffoldproteiner
JP4939926B2 (ja) 2003-02-14 2012-05-30 アノシス・インコーポレーテッド 抗体を生成し抗体レパートリーをスクリーニングするための方法とコンパウンド
WO2006058890A2 (en) * 2004-11-30 2006-06-08 Novo Nordisk A/S Method of producing antibodies
EP1910513B1 (en) * 2005-07-01 2016-08-10 John Schrader Methods of isolating antibody secreting cells from blood samples of immunized animals and generating monoclonal antibodies from said antibody secreting cells.
EP2121007A1 (en) 2006-12-21 2009-11-25 Cytos Biotechnology AG Circular ccr5 peptide conjugates and uses thereof
GB2456236B8 (en) 2007-03-22 2009-12-09 Heptares Therapeutics Ltd Stable muscarinic receptor mutants
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
PT3034608T (pt) 2010-06-22 2019-05-28 Regeneron Pharma Ratinhos expressando uma cadeia leve híbrida de imunoglobulina com uma região variável humana
ME02106B (me) 2011-02-25 2015-10-20 Regeneron Pharma Miševi sa adam6
EP2617732A1 (en) 2012-01-19 2013-07-24 Vib Vzw Tools and methods for expression of membrane proteins
MX353278B (es) 2012-03-06 2018-01-05 Regeneron Pharma Raton con cadena ligera comun.
ES2676827T3 (es) 2012-06-01 2018-07-25 Heptares Therapeutics Limited Ensayos
MX2014014891A (es) 2012-06-05 2015-06-17 Regeneron Pharma Metodos para hacer anticuerpos biespecificos completamente humanos usando una cadena ligera comun.
EP2745834B1 (en) 2012-12-18 2016-09-28 Jens Frauenfeld Salipro particles
HK1218550A1 (zh) 2013-03-13 2017-02-24 Regeneron Pharmaceuticals, Inc. 常見輕鏈小鼠
EP4545567A3 (en) 2013-03-13 2025-08-13 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US9850303B2 (en) 2013-03-15 2017-12-26 The Translational Genomics Research Institute Hybridoma clones and monoclonal antibodies to tetraspanin 8
ES2939555T3 (es) * 2014-11-14 2023-04-24 Regeneron Pharma Método para generar anticuerpos de alta afinidad
WO2017214089A1 (en) 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
EP3284460A1 (en) 2016-08-19 2018-02-21 Salipro Biotech AG Saposin lipoprotein particles and libraries from crude membranes
SG10201913483XA (en) 2016-11-04 2020-03-30 Regeneron Pharma Non-human animals having an engineered immunoglobulin lambda light chain locus
HUE060608T2 (hu) 2017-12-05 2023-03-28 Regeneron Pharma Genetikailag módosított immunglobulin lambda könnyûlánccal rendelkezõ egerek és azok alkalmazása
US20210214719A1 (en) 2018-05-31 2021-07-15 Kangti Pte. Ltd. A yeast phenotypic screening method for isolation of functional antibodies against g-protein coupled receptors
US20210299070A1 (en) 2018-09-21 2021-09-30 Jnana Therapeutics, Inc. Methods of treating creatine transporter deficiency
US20210371403A1 (en) 2018-09-21 2021-12-02 Jnana Therapeutics, Inc. Small molecules targeting mutant mammalian proteins
WO2020061476A1 (en) 2018-09-21 2020-03-26 Jnana Therapeutics, Inc. Small molecules targeting mutant mammalian proteins

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118027202A (zh) * 2024-03-14 2024-05-14 恺佧生物科技(上海)有限公司 结合slc13a5膜蛋白的抗体

Also Published As

Publication number Publication date
US20220195038A1 (en) 2022-06-23
JP2024501796A (ja) 2024-01-16
EP4267608A1 (en) 2023-11-01
AU2021409906A9 (en) 2024-10-10
US20250313624A1 (en) 2025-10-09
AU2021409906A1 (en) 2023-06-15
BR112023011689A2 (pt) 2023-10-31
MX2023007583A (es) 2023-07-07
WO2022140494A1 (en) 2022-06-30
KR20230124594A (ko) 2023-08-25
TW202242114A (zh) 2022-11-01
CA3197426A1 (en) 2022-06-30
IL303865A (en) 2023-08-01
US12371487B2 (en) 2025-07-29

Similar Documents

Publication Publication Date Title
JP7273904B2 (ja) 液性免疫応答の増強方法
TWI831365B (zh) 抗ｇｐｃ３抗體
US11505605B2 (en) T cell-redirected antigen-binding molecule for cells having immunosuppression function
JP7767291B2 (ja) 新規のｌｉｌｒｂ２抗体およびその使用
TWI597290B (zh) Cell injury-inducing therapeutic agent
US20250313624A1 (en) Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
CN114450292B (zh) 断裂型内含肽、使用其的重组多肽的制备方法
TW201938203A (zh) 靶向共有抗原之抗原結合蛋白
CN104031150A (zh) 抗bst2抗体
McDaniel et al. Repertoire, function, and structure of serological antibodies induced by the R21/Matrix-M malaria vaccine
CN114340660A (zh) 开发用于发现治疗性抗体的高效杂交瘤平台
CN102282256A (zh) 针对在细胞表面表达的蛋白质的抗体制作方法
US20120322083A1 (en) Antibody binding to abca1 polypeptide
HK40089086A (zh) 新型lilrb2抗体和其用途
HK40063709A (en) Developing an efficient hybridoma platform for therapeutic antibody discovery
EA043515B1 (ru) Анти-gpc3-антитело

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination